United States Biotechnology & Medical Research

Allogene Therapeutics Inc (ALLO)

Track

Track

Allogene Therapeutics experienced net selling activity totaling approximately $62,958 over the past ninety days. Following an earnings report that exceeded expectations by 18.75%, shares declined 30.2%. Recent transactions involved senior leadership offloading equity, reflecting a broader trend of divestment within the healthcare firm as the stock trades near its annual low.
Ticker: ALLO Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Allogene Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.8
Douglas Earl Martin SVP, General Counsel Officer
Transaction date
Sale
Price
240.99
Quantity 93,392 +21.6%
Value US$730,925
1.8
Douglas Earl Martin Officer Officer
Transaction date
Proposed sale
Price
33.25
Quantity 80,791
Value US$1,582,239
3.3
Yoshiyama Annie SVP, Finance Officer
Transaction date
Sale
Price
119.29
Quantity 16,561 +11.7%
Value US$974,685
3.3
Yoshiyama Annie Officer Officer
Transaction date
Proposed sale
Price
2.31
Quantity 9,586
Value US$22,103
3.4
Beneski Benjamin Machinas Officer Officer
Transaction date
Proposed sale
Price
2.50
Quantity 2,867
Value US$7,168
3.4
Beneski Benjamin Machinas SVP, Chief Technical Officer Officer
Transaction date
Sale
Price
2.50
Quantity 2,867 -1.4%
Value US$7,168
2.7
Chang David D President and CEO Executive Director
Transaction date
Sale
Price
2.47
Quantity 47,763 -0.9%
Value US$117,975
3.4
Beneski Benjamin Machinas SVP, Chief Technical Officer Officer
Transaction date
Sale
Price
2.47
Quantity 4,835 -2.4%
Value US$11,942
3.4
Beneski Benjamin Machinas Officer Officer
Transaction date
Proposed sale
Price
2.47
Quantity 4,835
Value US$11,928
2.7
Chang David D Officer Officer
Transaction date
Proposed sale
Price
2.47
Quantity 47,763
Value US$117,827
3.4
Beneski Benjamin Machinas SVP, Chief Technical Officer Officer
Transaction date
Sale
Price
2.60
Quantity 7,132 -3.4%
Value US$18,543
3.4
Beneski Benjamin Machinas Officer Officer
Transaction date
Proposed sale
Price
2.60
Quantity 7,132
Value US$18,541
3.4
Beneski Benjamin Machinas SVP, Chief Technical Officer Officer
Transaction date
Sale
Price
1.73
Quantity 7,549 -3.5%
Value US$13,060
1.8
Douglas Earl Martin SVP, General Counsel Officer
Transaction date
Sale
Price
1.76
Quantity 22,900 -3.9%
Value US$40,304
2.7
Chang David D President and CEO Executive Director
Transaction date
Sale
Price
1.80
Quantity 95,269 -1.8%
Value US$171,484
3.3
Yoshiyama Annie SVP, Finance Officer
Transaction date
Sale
Price
1.72
Quantity 4,167 -3.1%
Value US$7,167
1.9
Parker Geoffrey M. CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
1.76
Quantity 24,001 -1.9%
Value US$42,242
1.9
Roberts Zachary EVP of R&D Officer
Transaction date
Sale
Price
1.77
Quantity 35,700 -5.8%
Value US$63,189
1.8
EARL DOUGLAS Officer Officer
Transaction date
Proposed sale
Price
1.76
Quantity 22,900
Value US$40,215
1.9
GEOFFREY M PARKER Officer Officer
Transaction date
Proposed sale
Price
1.76
Quantity 24,001
Value US$42,189
1.9
ZACHARY J ROBERTS Officer Officer
Transaction date
Proposed sale
Price
1.77
Quantity 35,700
Value US$63,353
3.3
ANNIE T YOSHIYAMA Officer Officer
Transaction date
Proposed sale
Price
1.72
Quantity 4,167
Value US$7,178
2.7
DAVID CHANG Officer Officer
Transaction date
Proposed sale
Price
1.80
Quantity 243,976
Value US$438,522
3.4
BENJAMIN M BENESKI Officer Officer
Transaction date
Proposed sale
Price
1.73
Quantity 16,823
Value US$29,052
1.9
Roberts Zachary EVP of R&D Officer
Transaction date
Sale
Price
1.56
Quantity 26,269 -4.1%
Value US$40,980
1.9
Roberts Zachary Officer Officer
Transaction date
Proposed sale
Price
1.56
Quantity 26,269
Value US$40,929
3.4
Beneski Benjamin Machinas SVP, Chief Technical Officer Officer
Transaction date
Sale
Price
1.22
Quantity 786 -0.4%
Value US$959
3.4
Beneski Benjamin Machinas Officer Officer
Transaction date
Proposed sale
Price
1.22
Quantity 786
Value US$959
1.9
Parker Geoffrey M. CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
1.26
Quantity 36,744 -2.8%
Value US$46,169
1.9
Parker Geoffrey M. Officer Officer
Transaction date
Proposed sale
Price
1.26
Quantity 36,744
Value US$46,169
2.7
MESSEMER DEBORAH M. Non-Executive Director
Transaction date
Planned sale
Price
1.42
Quantity 36,885 -25.6%
Value US$52,377
2.7
MESSEMER DEBORAH M. Director Non-Executive Director
Transaction date
Proposed sale
Price
1.42
Quantity 36,885
Value US$52,391
3.3
Yoshiyama Annie SVP, Finance Officer
Transaction date
Sale
Price
1.41
Quantity 9,601 -6.8%
Value US$13,537
3.3
Yoshiyama Annie Officer Officer
Transaction date
Proposed sale
Price
1.41
Quantity 9,601
Value US$13,537
2.7
Chang David D President and CEO Executive Director
Transaction date
Sale
Price
1.96
Quantity 46,668 -0.9%
Value US$91,469
3.4
Beneski Benjamin Machinas SVP, Chief Technical Officer Officer
Transaction date
Sale
Price
1.98
Quantity 5,488 -2.5%
Value US$10,839
3.4
Beneski Benjamin Machinas Officer Officer
Transaction date
Proposed sale
Price
1.97
Quantity 5,488
Value US$10,839
2.7
Chang David D Officer Officer
Transaction date
Proposed sale
Price
1.96
Quantity 46,668
Value US$91,469
2.7
MESSEMER DEBORAH M. Non-Executive Director
Transaction date
Planned sale
Price
2.43
Quantity 13,313 -8.4%
Value US$32,351
2.7
MESSEMER DEBORAH M. Director Non-Executive Director
Transaction date
Proposed sale
Price
2.43
Quantity 13,313
Value US$32,329
1.9
Parker Geoffrey M. CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
1.73
Quantity 4,361 -0.3%
Value US$7,545
1.9
Roberts Zachary EVP of R&D Officer
Transaction date
Sale
Price
1.70
Quantity 18,832 -2.8%
Value US$32,014
2.7
Chang David D President and CEO Executive Director
Transaction date
Sale
Price
1.68
Quantity 46,003 -0.9%
Value US$77,285
1.8
Douglas Earl Martin SVP, General Counsel Officer
Transaction date
Sale
Price
1.71
Quantity 6,404 -1.1%
Value US$10,951
3.2
MOORE TIMOTHY L. Chief Technical Officer Officer
Transaction date
Sale
Price
1.71
Quantity 14,746 -5.6%
Value US$25,216
1.9
Roberts Zachary Officer Officer
Transaction date
Proposed sale
Price
1.70
Quantity 18,832
Value US$32,014
2.7
Chang David D Officer Officer
Transaction date
Proposed sale
Price
1.68
Quantity 46,003
Value US$77,446
1.8
Douglas Earl Martin Officer Officer
Transaction date
Proposed sale
Price
1.71
Quantity 6,404
Value US$10,951
3.2
MOORE TIMOTHY L. Officer Officer
Transaction date
Proposed sale
Price
1.71
Quantity 14,746
Value US$25,225
1.9
Parker Geoffrey M. Officer Officer
Transaction date
Proposed sale
Price
1.73
Quantity 4,361
Value US$7,545
1.9
Roberts Zachary EVP of R&D Officer
Transaction date
Sale
Price
1.78
Quantity 27,199 -5.3%
Value US$48,414
1.9
Roberts Zachary Officer Officer
Transaction date
Proposed sale
Price
1.78
Quantity 27,199
Value US$48,499
2.7
MESSEMER DEBORAH M. Non-Executive Director
Transaction date
Sale
Price
2.18
Quantity 9,136 -5.5%
Value US$19,916
2.7
MESSEMER DEBORAH M. Director Non-Executive Director
Transaction date
Proposed sale
Price
2.18
Quantity 9,136
Value US$19,954
2.3
Humer Franz B Director Non-Executive Director
Transaction date
Proposed sale
Price
2.30
Quantity 9,221
Value US$21,208
2.3
Humer Franz B Non-Executive Director
Transaction date
Sale
Price
2.16
Quantity 9,221 -2.9%
Value US$19,917
2.3
Humer Franz B Director Non-Executive Director
Transaction date
Proposed sale
Price
2.48
Quantity 9,221
Value US$22,868
1.9
Parker Geoffrey M. Officer Officer
Transaction date
Proposed sale
Price
2.84
Quantity 36,404
Value US$103,501
1.8
Douglas Earl Martin Officer Officer
Transaction date
Proposed sale
Price
2.79
Quantity 28,310
Value US$78,844
2.7
MESSEMER DEBORAH M. Non-Executive Director
Transaction date
Planned sale
Price
2.28
Quantity 18,641 -10.1%
Value US$42,488
2.7
MESSEMER DEBORAH M. Director Non-Executive Director
Transaction date
Proposed sale
Price
2.28
Quantity 18,641
Value US$42,489
2.3
Humer Franz B Non-Executive Director
Transaction date
Sale
Price
2.34
Quantity 11,200 -4.2%
Value US$26,181
2.3
Humer Franz B Director Non-Executive Director
Transaction date
Proposed sale
Price
2.47
Quantity 11,200
Value US$27,716
1.7
Belldegrun Arie Non-Executive Director
Transaction date
Purchase
Price
2.90
Quantity 1,724,137 +inf%
Value US$4,999,997
1.7
Belldegrun Arie Non-Executive Director
Transaction date
Purchase
Price
2.90
Quantity 1,724,137 +inf%
Value US$4,999,997
3.2
MOORE TIMOTHY L. Officer Officer
Transaction date
Proposed sale
Price
3.47
Quantity 17,360
Value US$60,190
2.7
Chang David D Officer Officer
Transaction date
Proposed sale
Price
4.33
Quantity 53,393
Value US$231,065
1.9
Parker Geoffrey M. CHIEF FINANCIAL OFFICER Officer
Transaction date
Purchase
Price
3.60
Quantity 190 +0.0%
Value US$683
1.9
Roberts Zachary Officer Officer
Transaction date
Proposed sale
Price
3.17
Quantity 24,690
Value US$78,376
2.7
MESSEMER DEBORAH M. Non-Executive Director
Transaction date
Planned sale
Price
2.70
Quantity 18,640 -23.0%
Value US$50,317
2.7
MESSEMER DEBORAH M. Director Non-Executive Director
Transaction date
Proposed sale
Price
2.70
Quantity 18,640
Value US$50,317
2.2
Mayo Stephen Non-Executive Director
Transaction date
Sale
Price
4.29
Quantity 10,000 -28.3%
Value US$42,855
2.2
Mayo Stephen Director Non-Executive Director
Transaction date
Proposed sale
Price
4.29
Quantity 10,000
Value US$42,855
3.3
Bhavnagri Veer Officer Officer
Transaction date
Proposed sale
Price
4.51
Quantity 39,305
Value US$177,122
3.3
Bhavnagri Veer Officer Officer
Transaction date
Proposed sale
Price
4.85
Quantity 72,995
Value US$354,026
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-25 2026-08-21 S Sale
1.8
Douglas Earl Martin

SVP, General Counsel

Officer
93,392 +21.6%
240.99
US$730,925 		93,392 +21.6% 240.99 US$730,925
2026-08-21 2026-08-21 PrS Proposed sale
1.8
Douglas Earl Martin

Officer

Officer
80,791
33.25
US$1,582,239 		80,791 33.25 US$1,582,239
2026-04-23 2026-04-21 S Sale
3.3
Yoshiyama Annie

SVP, Finance

Officer
16,561 +11.7%
119.29
US$974,685 		16,561 +11.7% 119.29 US$974,685
2026-04-21 2026-04-21 PrS Proposed sale
3.3
Yoshiyama Annie

Officer

Officer
9,586
2.31
US$22,103 		9,586 2.31 US$22,103
2026-04-01 2026-04-01 PrS Proposed sale
3.4
Beneski Benjamin Machinas

Officer

Officer
2,867
2.50
US$7,168 		2,867 2.50 US$7,168
2026-04-02 2026-03-31 S Sale
3.4
Beneski Benjamin Machinas

SVP, Chief Technical Officer

Officer
2,867 -1.4%
2.50
US$7,168 		2,867 -1.4% 2.50 US$7,168
2026-03-18 2026-03-16 S Sale
2.7
Chang David D

President and CEO

Executive Director
47,763 -0.9%
2.47
US$117,975 		47,763 -0.9% 2.47 US$117,975
2026-03-18 2026-03-16 S Sale
3.4
Beneski Benjamin Machinas

SVP, Chief Technical Officer

Officer
4,835 -2.4%
2.47
US$11,942 		4,835 -2.4% 2.47 US$11,942
2026-03-16 2026-03-16 PrS Proposed sale
3.4
Beneski Benjamin Machinas

Officer

Officer
4,835
2.47
US$11,928 		4,835 2.47 US$11,928
2026-03-16 2026-03-16 PrS Proposed sale
2.7
Chang David D

Officer

Officer
47,763
2.47
US$117,827 		47,763 2.47 US$117,827
2026-03-04 2026-03-02 S Sale
3.4
Beneski Benjamin Machinas

SVP, Chief Technical Officer

Officer
7,132 -3.4%
2.60
US$18,543 		7,132 -3.4% 2.60 US$18,543
2026-03-02 2026-03-02 PrS Proposed sale
3.4
Beneski Benjamin Machinas

Officer

Officer
7,132
2.60
US$18,541 		7,132 2.60 US$18,541
2026-02-04 2026-02-02 S Sale
3.4
Beneski Benjamin Machinas

SVP, Chief Technical Officer

Officer
7,549 -3.5%
1.73
US$13,060 		7,549 -3.5% 1.73 US$13,060
2026-02-04 2026-02-02 S Sale
1.8
Douglas Earl Martin

SVP, General Counsel

Officer
22,900 -3.9%
1.76
US$40,304 		22,900 -3.9% 1.76 US$40,304
2026-02-04 2026-02-02 S Sale
2.7
Chang David D

President and CEO

Executive Director
95,269 -1.8%
1.80
US$171,484 		95,269 -1.8% 1.80 US$171,484
2026-02-04 2026-02-02 S Sale
3.3
Yoshiyama Annie

SVP, Finance

Officer
4,167 -3.1%
1.72
US$7,167 		4,167 -3.1% 1.72 US$7,167
2026-02-04 2026-02-02 S Sale
1.9
Parker Geoffrey M.

CHIEF FINANCIAL OFFICER

Officer
24,001 -1.9%
1.76
US$42,242 		24,001 -1.9% 1.76 US$42,242
2026-02-04 2026-02-02 S Sale
1.9
Roberts Zachary

EVP of R&D

Officer
35,700 -5.8%
1.77
US$63,189 		35,700 -5.8% 1.77 US$63,189
2026-02-02 2026-02-02 PrS Proposed sale
1.8
EARL DOUGLAS

Officer

Officer
22,900
1.76
US$40,215 		22,900 1.76 US$40,215
2026-02-02 2026-02-02 PrS Proposed sale
1.9
GEOFFREY M PARKER

Officer

Officer
24,001
1.76
US$42,189 		24,001 1.76 US$42,189
2026-02-02 2026-02-02 PrS Proposed sale
1.9
ZACHARY J ROBERTS

Officer

Officer
35,700
1.77
US$63,353 		35,700 1.77 US$63,353
2026-02-02 2026-02-02 PrS Proposed sale
3.3
ANNIE T YOSHIYAMA

Officer

Officer
4,167
1.72
US$7,178 		4,167 1.72 US$7,178
2026-02-02 2026-02-02 PrS Proposed sale
2.7
DAVID CHANG

Officer

Officer
243,976
1.80
US$438,522 		243,976 1.80 US$438,522
2026-02-02 2026-02-02 PrS Proposed sale
3.4
BENJAMIN M BENESKI

Officer

Officer
16,823
1.73
US$29,052 		16,823 1.73 US$29,052
2026-01-23 2026-01-21 S Sale
1.9
Roberts Zachary

EVP of R&D

Officer
26,269 -4.1%
1.56
US$40,980 		26,269 -4.1% 1.56 US$40,980
2026-01-21 2026-01-21 PrS Proposed sale
1.9
Roberts Zachary

Officer

Officer
26,269
1.56
US$40,929 		26,269 1.56 US$40,929
2025-11-19 2025-11-17 S Sale
3.4
Beneski Benjamin Machinas

SVP, Chief Technical Officer

Officer
786 -0.4%
1.22
US$959 		786 -0.4% 1.22 US$959
2025-11-17 2025-11-17 PrS Proposed sale
3.4
Beneski Benjamin Machinas

Officer

Officer
786
1.22
US$959 		786 1.22 US$959
2025-10-23 2025-10-21 S Sale
1.9
Parker Geoffrey M.

CHIEF FINANCIAL OFFICER

Officer
36,744 -2.8%
1.26
US$46,169 		36,744 -2.8% 1.26 US$46,169
2025-10-21 2025-10-21 PrS Proposed sale
1.9
Parker Geoffrey M.

Officer

Officer
36,744
1.26
US$46,169 		36,744 1.26 US$46,169
2025-06-12 2025-06-10 PlS Planned sale
2.7
MESSEMER DEBORAH M.
Non-Executive Director
36,885 -25.6%
1.42
US$52,377 		36,885 -25.6% 1.42 US$52,377
2025-06-10 2025-06-10 PrS Proposed sale
2.7
MESSEMER DEBORAH M.

Director

Non-Executive Director
36,885
1.42
US$52,391 		36,885 1.42 US$52,391
2025-04-23 2025-04-21 S Sale
3.3
Yoshiyama Annie

SVP, Finance

Officer
9,601 -6.8%
1.41
US$13,537 		9,601 -6.8% 1.41 US$13,537
2025-04-21 2025-04-21 PrS Proposed sale
3.3
Yoshiyama Annie

Officer

Officer
9,601
1.41
US$13,537 		9,601 1.41 US$13,537
2025-03-18 2025-03-14 S Sale
2.7
Chang David D

President and CEO

Executive Director
46,668 -0.9%
1.96
US$91,469 		46,668 -0.9% 1.96 US$91,469
2025-03-18 2025-03-14 S Sale
3.4
Beneski Benjamin Machinas

SVP, Chief Technical Officer

Officer
5,488 -2.5%
1.98
US$10,839 		5,488 -2.5% 1.98 US$10,839
2025-03-14 2025-03-14 PrS Proposed sale
3.4
Beneski Benjamin Machinas

Officer

Officer
5,488
1.97
US$10,839 		5,488 1.97 US$10,839
2025-03-14 2025-03-14 PrS Proposed sale
2.7
Chang David D

Officer

Officer
46,668
1.96
US$91,469 		46,668 1.96 US$91,469
2025-02-20 2025-02-18 PlS Planned sale
2.7
MESSEMER DEBORAH M.
Non-Executive Director
13,313 -8.4%
2.43
US$32,351 		13,313 -8.4% 2.43 US$32,351
2025-02-18 2025-02-18 PrS Proposed sale
2.7
MESSEMER DEBORAH M.

Director

Non-Executive Director
13,313
2.43
US$32,329 		13,313 2.43 US$32,329
2025-02-05 2025-02-03 S Sale
1.9
Parker Geoffrey M.

CHIEF FINANCIAL OFFICER

Officer
4,361 -0.3%
1.73
US$7,545 		4,361 -0.3% 1.73 US$7,545
2025-02-05 2025-02-03 S Sale
1.9
Roberts Zachary

EVP of R&D

Officer
18,832 -2.8%
1.70
US$32,014 		18,832 -2.8% 1.70 US$32,014
2025-02-05 2025-02-03 S Sale
2.7
Chang David D

President and CEO

Executive Director
46,003 -0.9%
1.68
US$77,285 		46,003 -0.9% 1.68 US$77,285
2025-02-05 2025-02-03 S Sale
1.8
Douglas Earl Martin

SVP, General Counsel

Officer
6,404 -1.1%
1.71
US$10,951 		6,404 -1.1% 1.71 US$10,951
2025-02-05 2025-02-03 S Sale
3.2
MOORE TIMOTHY L.

Chief Technical Officer

Officer
14,746 -5.6%
1.71
US$25,216 		14,746 -5.6% 1.71 US$25,216
2025-02-03 2025-02-03 PrS Proposed sale
1.9
Roberts Zachary

Officer

Officer
18,832
1.70
US$32,014 		18,832 1.70 US$32,014
2025-02-03 2025-02-03 PrS Proposed sale
2.7
Chang David D

Officer

Officer
46,003
1.68
US$77,446 		46,003 1.68 US$77,446
2025-02-03 2025-02-03 PrS Proposed sale
1.8
Douglas Earl Martin

Officer

Officer
6,404
1.71
US$10,951 		6,404 1.71 US$10,951
2025-02-03 2025-02-03 PrS Proposed sale
3.2
MOORE TIMOTHY L.

Officer

Officer
14,746
1.71
US$25,225 		14,746 1.71 US$25,225
2025-02-03 2025-02-03 PrS Proposed sale
1.9
Parker Geoffrey M.

Officer

Officer
4,361
1.73
US$7,545 		4,361 1.73 US$7,545
2025-01-23 2025-01-21 S Sale
1.9
Roberts Zachary

EVP of R&D

Officer
27,199 -5.3%
1.78
US$48,414 		27,199 -5.3% 1.78 US$48,414
2025-01-21 2025-01-21 PrS Proposed sale
1.9
Roberts Zachary

Officer

Officer
27,199
1.78
US$48,499 		27,199 1.78 US$48,499
2024-12-10 2024-12-09 S Sale
2.7
MESSEMER DEBORAH M.
Non-Executive Director
9,136 -5.5%
2.18
US$19,916 		9,136 -5.5% 2.18 US$19,916
2024-12-09 2024-12-09 PrS Proposed sale
2.7
MESSEMER DEBORAH M.

Director

Non-Executive Director
9,136
2.18
US$19,954 		9,136 2.18 US$19,954
2024-12-04 2024-12-06 PrS Proposed sale
2.3
Humer Franz B

Director

Non-Executive Director
9,221
2.30
US$21,208 		9,221 2.30 US$21,208
2024-12-09 2024-12-05 S Sale
2.3
Humer Franz B
Non-Executive Director
9,221 -2.9%
2.16
US$19,917 		9,221 -2.9% 2.16 US$19,917
2024-12-02 2024-12-03 PrS Proposed sale
2.3
Humer Franz B

Director

Non-Executive Director
9,221
2.48
US$22,868 		9,221 2.48 US$22,868
2024-10-21 2024-10-21 PrS Proposed sale
1.9
Parker Geoffrey M.

Officer

Officer
36,404
2.84
US$103,501 		36,404 2.84 US$103,501
2024-08-21 2024-08-21 PrS Proposed sale
1.8
Douglas Earl Martin

Officer

Officer
28,310
2.79
US$78,844 		28,310 2.79 US$78,844
2024-06-20 2024-06-18 PlS Planned sale
2.7
MESSEMER DEBORAH M.
Non-Executive Director
18,641 -10.1%
2.28
US$42,488 		18,641 -10.1% 2.28 US$42,488
2024-06-18 2024-06-18 PrS Proposed sale
2.7
MESSEMER DEBORAH M.

Director

Non-Executive Director
18,641
2.28
US$42,489 		18,641 2.28 US$42,489
2024-06-03 2024-05-30 S Sale
2.3
Humer Franz B
Non-Executive Director
11,200 -4.2%
2.34
US$26,181 		11,200 -4.2% 2.34 US$26,181
2024-05-29 2024-05-29 PrS Proposed sale
2.3
Humer Franz B

Director

Non-Executive Director
11,200
2.47
US$27,716 		11,200 2.47 US$27,716
2024-05-20 2024-05-16 B Purchase
1.7
Belldegrun Arie
Non-Executive Director
1,724,137 +inf%
2.90
US$4,999,997 		1,724,137 +inf% 2.90 US$4,999,997
2024-05-20 2024-05-16 B Purchase
1.7
Belldegrun Arie
Non-Executive Director
1,724,137 +inf%
2.90
US$4,999,997 		1,724,137 +inf% 2.90 US$4,999,997
2024-04-22 2024-04-22 PrS Proposed sale
3.2
MOORE TIMOTHY L.

Officer

Officer
17,360
3.47
US$60,190 		17,360 3.47 US$60,190
2024-03-14 2024-03-14 PrS Proposed sale
2.7
Chang David D

Officer

Officer
53,393
4.33
US$231,065 		53,393 4.33 US$231,065
2024-03-06 2024-01-30 B Purchase
1.9
Parker Geoffrey M.

CHIEF FINANCIAL OFFICER

Officer
190 +0.0%
3.60
US$683 		190 +0.0% 3.60 US$683
2024-01-22 2024-01-22 PrS Proposed sale
1.9
Roberts Zachary

Officer

Officer
24,690
3.17
US$78,376 		24,690 3.17 US$78,376
2023-12-20 2023-12-18 PlS Planned sale
2.7
MESSEMER DEBORAH M.
Non-Executive Director
18,640 -23.0%
2.70
US$50,317 		18,640 -23.0% 2.70 US$50,317
2023-12-18 2023-12-18 PrS Proposed sale
2.7
MESSEMER DEBORAH M.

Director

Non-Executive Director
18,640
2.70
US$50,317 		18,640 2.70 US$50,317
2023-08-09 2023-08-07 S Sale
2.2
Mayo Stephen
Non-Executive Director
10,000 -28.3%
4.29
US$42,855 		10,000 -28.3% 4.29 US$42,855
2023-08-07 2023-08-07 PrS Proposed sale
2.2
Mayo Stephen

Director

Non-Executive Director
10,000
4.29
US$42,855 		10,000 4.29 US$42,855
2023-06-29 2023-06-28 PrS Proposed sale
3.3
Bhavnagri Veer

Officer

Officer
39,305
4.51
US$177,122 		39,305 4.51 US$177,122
2023-06-20 2023-06-20 PrS Proposed sale
3.3
Bhavnagri Veer

Officer

Officer
72,995
4.85
US$354,026 		72,995 4.85 US$354,026
Explore more

More insider trading research around Allogene Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America